OncoTAb Names Dr. David L. Cooper as COO

Share Article

OncoTAb, Inc., a University of North Carolina at Charlotte (UNC Charlotte) spin-out company, announced today the appointment of physician and scientist David L. Cooper, Ph.D., M.D., as Chief Operating Officer (COO).

David L. Cooper, Ph.D., M.D., Chief Operating Officer, OncoTAb Inc.

David L. Cooper, Ph.D., M.D., Chief Operating Officer, OncoTAb Inc.

"I'm honored to join an organization dedicated to revolutionizing the treatment and care of cancer patients."

OncoTAb, Inc., a University of North Carolina at Charlotte (UNC Charlotte) spin-out company, announced today the appointment of physician and scientist David L. Cooper, Ph.D., M.D., as Chief Operating Officer (COO). Cooper brings to OncoTAb more than 20 years of experience in developing clinical diagnostic and biotechnology platforms in the fields of genetics, oncology and infectious disease.

Cooper’s extensive career transcends the field of medical and scientific research. In addition to building biotechnology, diagnostic and pharmaceutical programs from the ground up, he co-founded and served as the first President of the Association for Molecular Pathology (AMP) and was the founding editor of the Journal of Molecular Diagnosis and Therapy.

Prior to joining OncoTAb, Cooper served seven years as President and CEO of NanoMedex Pharmaceuticals, Inc. Other previous positions include Chief Medical Officer (CMO) for NimbleGen Systems Inc., and Chief Science Officer of Quest Diagnostics and the Nichols Institute. Cooper also served as a tenured Professor of Pathology at the University of Pittsburgh Medical Center.

“I’m honored to join an organization dedicated to revolutionizing the treatment and care of cancer patients,” said Cooper. “Throughout my career, my efforts have focused on the application of the developing science and advances in biotechnology to the practice of modern medicine. Serving as COO for OncoTAb provides me the exciting opportunity to continue making a difference in the lives of patients and their families.”

“Dr. Cooper has amassed an outstanding career record of innovative ideas and inspiring leadership that, along with his deep medical and scientific knowledge, will be invaluable to OncoTAb’s future,” said OncoTAb CEO Rahul Puri. “We are thrilled to have him as part of our executive team and look forward to the many contributions he will make to the company and our cancer technologies.”

Cooper received his medical degree from the University of Florida and a graduate degree in chemistry from Florida State University. He is the recipient of the Litchfield Lectureship, Nuffield Department of Pathology, John Radcliffe Hospital, Oxford.

This press release is neither an offer to sell nor the solicitation of an offer to buy shares or any other security in any jurisdiction.

About OncoTAb, Inc.
OncoTAb (http://www.oncotab.com) is a University of North Carolina at Charlotte (UNC Charlotte) spin-out that has licensed a patent-protected technology from the university. Its applications span the life cycle of cancer patients, from detecting and locating cancer to treatment and monitoring for recurrence. The company is gearing up for a pivotal clinical study of its blood test and is pursuing additional diagnostic, imaging, and therapeutic product development and commercialization in the cancer space.

Share article on socal media or email:

View article via:

Pdf Print

Contact Author

Liz Roop